Eureka Biotechnology Co., Limited

Here's why this FDA milestone is a game-changer for EurekaBio: The approval of our self-developed EuLV Packaging Cell Line（EuLV PCL）receiving DMF acknowledgement by FDA is not just a badge of honor but a catalyst for innovation in gene and cell therapy. This signifies our technical prowess and sets the stage for groundbreaking advancements in CGT. 💪 Our EuLV packaging cell line, pivotal to this DMF, is designed for large-scale, high-quality production, addressing the soaring demand for robust viral vectors. This achievement simplifies the drug application process, reducing preparation time and minimizing risks, ensuring faster approvals for our clients. Moreover, this milestone enhances our credibility, paving the way for international expansion. It underscores our commitment to delivering top-tier bio-pharmaceutical solutions and propelling the industry forward. As we celebrate this achievement, we're poised to explore new horizons and contribute to global healthcare innovation. Let's connect and discuss the future of bio-pharmaceuticals! Share your thoughts or drop a comment below. 🌟

🚀 EurekaBio’s EuLV™ Stable Lentiviral Vector Production System: A Game Changer for CAR-T Therapy! 🚀 We’re thrilled to share that Ucello Biotechnology's allogeneic CAR-T therapy (UC101), targeting CD19, has received FDA IND approval for clinical trials as of January 11th, 2025. This milestone is a major leap forward in the development of next-generation cell therapies! 🎉 UC101 was developed using EurekaBio’s EuLV™ lentiviral vector stable producer cell line production system, which has played a pivotal role in reducing costs, improving consistency, and enhancing the overall quality of lentiviral vector production—transforming the way lentiviral vectors are manufactured. This collaboration between Ucello and EurekaBio is accelerating the future of CAR-T therapy by streamlining production and making it more cost-effective, without compromising on quality. 🔬 EuLV™ Key Highlights: • EuLV™ simplifies vector production by skipping GMP plasmid and transfection reagent • EuLV™ increase the titer by 10 to 100 folders in Supernatant • EuLV™ increase the viral quality • FDA IND approved • DMF acknowledgement received Let’s celebrate this breakthrough and stay tuned for more updates on the future of CAR-T therapies! 🙌 Interested in learning more? Reach out to us today! #FDA #IND #CART #CellTherapy #BioInnovation For more on EuLV™ please click the link down below: https://lnkd.in/gTfW7rx6

Here's why this FDA milestone is a game-changer for EurekaBio: The approval of our self-developed EuLV Packaging Cell Line（EuLV PCL）receiving DMF acknowledgement by FDA is not just a badge of honor but a catalyst for innovation in gene and cell therapy. This signifies our technical prowess and sets the stage for groundbreaking advancements in CGT. 💪 Our EuLV packaging cell line, pivotal to this DMF, is designed for large-scale, high-quality production, addressing the soaring demand for robust viral vectors. This achievement simplifies the drug application process, reducing preparation time and minimizing risks, ensuring faster approvals for our clients. Moreover, this milestone enhances our credibility, paving the way for international expansion. It underscores our commitment to delivering top-tier bio-pharmaceutical solutions and propelling the industry forward. As we celebrate this achievement, we're poised to explore new horizons and contribute to global healthcare innovation. Let's connect and discuss the future of bio-pharmaceuticals! Share your thoughts or drop a comment below. 🌟

Reducing the cost of cell therapy drug production is crucial for the future of cell therapy. Join Roy LIU, CMO of EurekaBio, at the JPM Healthcare Conference to discuss groundbreaking insights into how EuLV technology is revolutionizing the efficiency and quality of cell therapy drug production. EuLV technology simplifies processes, reduces expenses, and enhances patient outcomes, offering a transformative advancement for companies eager to deliver superior solutions faster. Don't miss the chance to learn more. Visit JPM2025 to see how EurekaBio is redefining the future of cell therapy in healthcare! 🌟 #HealthcareRevolution #JPMHealthConference

🌿 Proud moment for EurekaBio: We've secured a silver certification in the 2024 EcoVadis CSR rating! Discover our journey to the top 5%! 🌟 We're excited to share that EurekaBio has earned a silver certification in the 2024 EcoVadis social responsibility rating, placing us in the top 15% of all evaluated companies and the top 5% in our industry. This accolade highlights our excellence in corporate social responsibility and sustainable development. EcoVadis, a global leader in CSR ratings, assessed our performance across 21 indicators in four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. At EurekaBio, we prioritize CSR and sustainable practices to support innovative therapies, enhance patient access, and address unmet medical needs. Our commitment to continuous improvement drives us to create lasting value for society, the environment, and our company, advancing biotechnology and treatment frontiers.

Unlock the future of biotech with cost-saving innovations—meet us at Booth #33 at the CAR-TCR Summit in Boston! 🚀 From September 18-19, our Director of Business Development, Vikki MI, will be at Booth #33. Discover our latest innovations that can cut your viral vector production costs by 80% and explore our fully automated cell processing system. Don't miss this opportunity to see how we can transform your operations. Visit us and learn more!

Discover how closed, automated cell processing systems are revolutionizing cell therapy—read our case study now! 🚀🔬 The cell therapy drug market is witnessing unprecedented growth, driven by relentless technological advancements and expanding clinical applications. This surge has introduced numerous groundbreaking therapies to the public. However, this booming sector faces significant challenges. The high personalization and complexity of cell therapy products lead to steep production costs, pushing companies to develop cost-effective manufacturing processes without compromising therapeutic efficacy. Additionally, stringent regulatory frameworks demand exceptional safety and consistency, as even minor contaminations or variations can jeopardize treatment outcomes and patient safety. Furthermore, the industry grapples with a shortage of skilled professionals and the high costs associated with their training. Amid these challenges, fully closed, automated cell processing systems present a vital solution for cell therapy companies, enabling them to overcome obstacles and drive industry progress. Interested in how you can use a closed, automated cell processing system for PBMC separation? Click the link to explore our Case Study https://lnkd.in/g5Vqp-v6

Here's a quick peek 👀 of how we celebrate our unique culture at EurekaBio:   At EurekaBio, we believe in celebrating not just our achievements, but also our journey. This year marks a decade of innovation and growth, and we're thrilled to share a special tradition we've cultivated - 'Lychee Day'. 🍇   Lychee Day isn't just about taking a time off and enjoying the delicious fruit. It's about taking a step back to appreciate our collective efforts, fostering team spirit, and recognizing the unique contributions of each member. Over the years, this day has become a symbol of our unity and our commitment to creating a vibrant work culture.   Whether it's through fun activities, team-building exercises, or simply sharing stories and laughs, Lychee Day has become a cherished part of EurekaBio's identity. It reminds us that our strength lies in our people and the bonds we form.   Celebrating Lychee Day is more than a tradition; it's a testament to our values and the people who make EurekaBio exceptional.   How do you celebrate your company's culture? Share your unique traditions in the comments below! 🚀   #CompanyCulture #TeamSpirit #EurekaBio #LycheeDay

Here's a super simple tip that helps us achieve breakthroughs in biotech: EuLV™ is revolutionizing viral vector production, offering unprecedented efficiency, quality and scalability. As the biotech landscape evolves, it's crucial to stay ahead with cutting-edge solutions. Our CMO Roy LIU will be at BPD from 8th-10th August to discuss how EuLV™ can transform your production processes. Plus, we're excited to announce a new project launching soon, designed to help more biotech companies experience the benefits of this groundbreaking technology! 🚀 Don't miss the chance to connect and explore how EuLV™ can elevate your operations. Looking forward to meeting and brainstorming innovative ideas together! Let's elevate biotech—one vector at a time. Comment below or message me to set up a meeting!

Unlock the future of cell & gene therapy with the EuLV™ System—achieve viral vector titers like never before! 🚀 #Biotech #Innovation #EuLV Discover the impressive capabilities of the EuLV™ System in generating high-titer, high-quality lentiviral vectors. Our application note demonstrates that the AntiCD19-CAR producer cell line, utilizing the EuLV™ System, easily achieved lentivirus titers of 8.13E10 TU/L in a 1L wave bioreactor before purification. Ready to elevate your viral vector production to this level? Contact us for a personalized consultation and take your cell & gene therapy projects to new heights! Explore more on https://lnkd.in/gBEaxrcN